Author:
Rowe Alexander K,de León Gabriel F Ponce,Mihigo Jules,Santelli Ana Carolina FS,Miller Nathan P,Van-Dúnem Pedro
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference29 articles.
1. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL: Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005, 2: e330-10.1371/journal.pmed.0020330.
2. Olumese P: Global Antimalarial Drug Policy Database. Antimalarial treatment policies for P. falciparum and P. vivax by country in WHO Africa and Easter Mediterranean Regions. [May 2008 Update]. (accessed September 1, 2009)., [
http://apps.who.int/malaria/treatmentpolicies.html
]
3. Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW: Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross-sectional study. BMJ. 2005, 331: 734-7. 10.1136/bmj.331.7519.734.
4. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW: Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J. 2007, 6: 31-10.1186/1475-2875-6-31.
5. Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda P, Sipilinyambe N, Simon JL, Snow RW: Improved diagnostic testing and malaria treatment practices in Zambia. JAMA. 2007, 297: 2227-2231. 10.1001/jama.297.20.2227.